Rapcabtagene autoleucel clinical trials
Also written YTB323.
How each study uses rapcabtagene autoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rapcabtagene autoleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 1
Studies
Open first, then newest update. How each study uses rapcabtagene autoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)RecruitingPhase 1Stanford UniversityNCT07443137Written as Rapcabtagene autoleucel (YTB323)
- An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus ErythematosusCompletedPhase 1/2Novartis PharmaceuticalsNCT05798117Written as YTB323
- Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)Active, not recruitingPhase 1/2Novartis PharmaceuticalsNCT06675864Written as rapcabtagene autoleucel (YTB323)
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPAActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06868290Written as Rapcabtagene autoleucel
- A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's DiseaseActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT07048197Written as Rapcabtagene autoleucel
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06655896Written as rapcabtagene autoleucel
- A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Active, not recruitingPhase 2Novartis PharmaceuticalsNCT06581198Written as rapcabtagene autoleucel
- An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple SclerosisActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT06617793Written as rapcabtagene autoleucel (YTB323)
- Phase 2 Study of Rapcabtagene Autoleucel in MyositisActive, not recruitingPhase 2Novartis PharmaceuticalsNCT06665256Written as Rapcabtagene autoleucel
Codes
What other systems call rapcabtagene autoleucel · ClinicalTrials.gg INT016468
- UNII (FDA) EJG3KK52YPRAPCABTAGENE AUTOLEUCELOne source FDA
- NCI Thesaurus C175534Rapcabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | EJG3KK52YP | RAPCABTAGENE AUTOLEUCEL | One source FDA |
| NCI Thesaurus | C175534 | Rapcabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.